Skip to content
Screener

Wave Life Sciences WVE Total Liabilities & Equity

Total Liabilities & Equity at other companies

Eli Lilly logo
Eli LillyLLY
$142.28B+41.0%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$3.19B-13.4%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$2.99B+0.3%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
$1.24B+22.6%
ALN
Alnylam PharmaceuticalsALNY
$5.56B+21.7%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$1.48B+0.9%

Other financials

Income statement

See full
Revenue$2.3M-73.9%
Operating income-$73.8M-39.9%
Net income-$69.4M-37.4%
EPS (diluted)-$0.34-9.7%

Balance sheet

See full
Cash & equivalents$368.0M+76.5%
Total debt$43.6M+101%
Total equity$453.5M+226%
Total assets$558.3M+121%

Cash flow

See full
Operating cash flow-$53.6M-16.5%
CapEx$884.0K+189%
Free cash flow-$54.5M-17.6%

Valuation

See full
Market cap$1.2B-7.3%
Enterprise value$877.58M-21.0%
P/S20.6×-16.6×

Profitability

See full
Operating margin-75.7%-33.6pp
Net margin-66.5%-29.9pp
FCF margin-27.2%-12.6pp

Returns & leverage

See full
Return on equity-68.3%
Debt / equity0.1×-0.1×
Current ratio10×+7.4×

Where this comes from

Reported directly by Wave Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 7:50 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324949
Line itemJune 30, 2026December 31, 2025
Series A preferred shares, no par value; nil and 3,901,348 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively$7,874
Shareholders’ equity:
Ordinary shares, no par value; 193,277,622 and 187,660,263 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively$1,627,209$1,616,478
Additional paid-in capital248,161228,365
Accumulated other comprehensive loss(172)(250)
Accumulated deficit(1,421,678)(1,326,236)
Total shareholders’ equity$453,520$518,357
Total liabilities, Series A preferred shares, and shareholders’ equity$558,321$638,499

Item 1. Financial Statements

FAQ

What is Wave Life Sciences's total liabilities & equity?
Wave Life Sciences (WVE) reported total liabilities & equity of $558.32M in Q2 2026.
How has Wave Life Sciences's total liabilities & equity changed year-over-year?
Wave Life Sciences's total liabilities & equity increased by 121.2% year-over-year, from $252.36M to $558.32M.
What is the long-term trend for Wave Life Sciences's total liabilities & equity?
Over 5 years (2020 to 2025), Wave Life Sciences's total liabilities & equity has grown at a 18.0% compound annual growth rate (CAGR), from $279.24M to $638.5M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Wave Life Sciences's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude